FIRST-INHUMAN STUDY OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IRAK1/4 INHIBITOR R835 IN HEALTHY SUBJECTS

被引：2
|
作者：
Yan, L. [1 ]
Tong, S. [1 ]
Absalom, A. [2 ]
Daas, I. D. [3 ]
Park, G. [1 ]
Taylor, V. [1 ]
Chow, D. [1 ]
Lee, M. [1 ]
Zheng, H. [1 ]
Chow, A. [1 ]
机构：
[1] Rigel Pharmaceut Inc, San Francisco, CA USA
[2] Univ Med Ctr Groningen, Groningen, Netherlands
[3] QPS Netherlands BV, Groningen, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.4590
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0219
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [41] Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
    Roedder, Silke
    Wendt, Emily
    Burris, Chad
    Nazareon, Jonathan
    Park, Grace
    Pangilinan, Phil
    Huang, Gianna
    Mathur, Anubhav
    Taylor, James
    Billin, Andrew
    Matzkies, Franziska
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 371 - 372
  • [42] Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects
    Bellaire, Susan
    Walzer, Mark
    Wang, Tianli
    Krauwinkel, Walter
    Yuan, Nancy
    Marek, Gerard J.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (03): : 291 - 301
  • [43] Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
    Weisel, Kathleen
    Scott, Nicola E.
    Tompson, Debra J.
    Votta, Bartholomew J.
    Madhavan, Sujith
    Povey, Kat
    Wolstenholme, Allen
    Simeoni, Monica
    Rudo, Todd
    Richards-Peterson, Lauren
    Sahota, Tarjinder
    Wang, J. Gene
    Lich, John
    Finger, Joshua
    Verticelli, Adeline
    Reilly, Michael
    Gough, Peter J.
    Harris, Philip A.
    Bertin, John
    Wang, Mei-Lun
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2017, 5 (06):
  • [44] Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects
    Vandell, Alexander G.
    Inoue, Satoshi
    Dennie, Justin
    Nagasawa, Yasuo
    Gajee, Roohi
    Pav, Joe
    Zhang, George
    Zamora, Cynthia
    Masuda, Nobuhisa
    Senaldi, Giorgio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (05)
  • [45] Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
    Frost, Charles
    Wang, Jessie
    Nepal, Sunil
    Schuster, Alan
    Barrett, Yu Chen
    Mosqueda-Garcia, Rogelio
    Reeves, Richard A.
    LaCreta, Frank
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 476 - 487
  • [46] Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects
    Kadokura, Takeshi
    Oikawa, Keishi
    Miyata, Koji
    Murase, Toshinobu
    Nakamura, Mashio
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (04): : 328 - 335
  • [47] Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects
    Kadokura, Takeshi
    Kashiwa, Makoto
    Groenendaal, Dorien
    Heeringa, Marten
    Mol, Roelof
    Verheggen, Frank
    Garcia-Hernandez, Alberto
    Onkels, Hartmut
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (08) : 431 - 441
  • [48] Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
    Nuggehally R. Srinivas
    Clinical Drug Investigation, 2019, 39 : 105 - 107
  • [49] Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects
    Geven, Christopher
    van Lier, Dirk
    Blet, Alice
    Peelen, Roel
    ten Elzen, Bas
    Mebazaa, Alexandre
    Kox, Matthijs
    Pickkers, Peter
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (09) : 2129 - 2141
  • [50] Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
    Zhao, Xia
    Sun, Peihong
    Zhou, Ying
    Liu, Yuwang
    Zhang, Huilin
    Mueck, Wolfgang
    Kubitza, Dagmar
    Bauer, Richard J.
    Zhang, Hong
    Cui, Yimin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) : 77 - 88
12345